JP2012502037A

JP2012502037A - ホウ素含有小分子

ホウ素含有小分子 Download PDF

Info

Publication number: JP2012502037A
Authority: JP; Japan
Prior art keywords: exemplary embodiment; substituted; unsubstituted; compound; group
Prior art date: 2008-09-04
Legal status : Pending

Application number

JP2011526134A

Other languages

English (en)

Japanese (ja)

Other versions

JP2012502037A5 (US20070167479A1-20070719-C00034.png

JP2012502037A6 (ja

Inventor

勉赤間

プラットナー，ジェイコブ，ジェイ．

Original Assignee

アナコールファーマシューティカルズ，インコーポレイテッド

Priority date

2008-09-04

Filing date

2009-09-10

Publication date

2012-01-26

2009-09-10 Application filed by アナコールファーマシューティカルズ，インコーポレイテッド filed Critical アナコールファーマシューティカルズ，インコーポレイテッド

2012-01-26 Publication of JP2012502037A publication Critical patent/JP2012502037A/ja

2012-06-07 Publication of JP2012502037A6 publication Critical patent/JP2012502037A6/ja

2012-10-18 Publication of JP2012502037A5 publication Critical patent/JP2012502037A5/ja

Status Pending legal-status Critical Current

Links

229910052796 boron Inorganic materials 0.000 title description 17
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 title description 14
150000003384 small molecules Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 392
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 39
102000004127 Cytokines Human genes 0.000 claims description 133
108090000695 Cytokines Proteins 0.000 claims description 133
238000000034 method Methods 0.000 claims description 110
-1 Gro- [alpha] Proteins 0.000 claims description 98
125000000217 alkyl group Chemical group 0.000 claims description 95
239000000203 mixture Substances 0.000 claims description 77
150000003839 salts Chemical class 0.000 claims description 68
201000004681 Psoriasis Diseases 0.000 claims description 63
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 47
102000019034 Chemokines Human genes 0.000 claims description 44
108010012236 Chemokines Proteins 0.000 claims description 44
125000003118 aryl group Chemical group 0.000 claims description 44
239000002552 dosage form Substances 0.000 claims description 42
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims description 39
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims description 39
125000004404 heteroalkyl group Chemical group 0.000 claims description 37
230000002829 reductive effect Effects 0.000 claims description 36
125000001072 heteroaryl group Chemical group 0.000 claims description 35
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 34
108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims description 33
102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims description 33
MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims description 31
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 31
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 31
241001465754 Metazoa Species 0.000 claims description 30
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 29
125000000753 cycloalkyl group Chemical group 0.000 claims description 28
238000009472 formulation Methods 0.000 claims description 27
206010039073 rheumatoid arthritis Diseases 0.000 claims description 26
108010002350 Interleukin-2 Proteins 0.000 claims description 25
102000000588 Interleukin-2 Human genes 0.000 claims description 25
201000006417 multiple sclerosis Diseases 0.000 claims description 24
102000003814 Interleukin-10 Human genes 0.000 claims description 22
108090000174 Interleukin-10 Proteins 0.000 claims description 22
102000013264 Interleukin-23 Human genes 0.000 claims description 22
108010065637 Interleukin-23 Proteins 0.000 claims description 22
230000002401 inhibitory effect Effects 0.000 claims description 22
108090001005 Interleukin-6 Proteins 0.000 claims description 20
102000004889 Interleukin-6 Human genes 0.000 claims description 20
229910052736 halogen Inorganic materials 0.000 claims description 20
230000000699 topical effect Effects 0.000 claims description 20
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 19
229910052739 hydrogen Inorganic materials 0.000 claims description 19
150000002367 halogens Chemical class 0.000 claims description 18
102100037850 Interferon gamma Human genes 0.000 claims description 17
108010074328 Interferon-gamma Proteins 0.000 claims description 17
108090000978 Interleukin-4 Proteins 0.000 claims description 17
102000013462 Interleukin-12 Human genes 0.000 claims description 16
108010065805 Interleukin-12 Proteins 0.000 claims description 16
108010002616 Interleukin-5 Proteins 0.000 claims description 15
108010037622 Type 7 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims description 15
102000010984 Type 7 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims description 15
108090001007 Interleukin-8 Proteins 0.000 claims description 14
239000000546 pharmaceutical excipient Substances 0.000 claims description 14
102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 12
101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 12
206010003246 arthritis Diseases 0.000 claims description 11
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 11
229960002986 dinoprostone Drugs 0.000 claims description 11
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 11
125000004093 cyano group Chemical group *C#N 0.000 claims description 9
206010007559 Cardiac failure congestive Diseases 0.000 claims description 8
206010019280 Heart failures Diseases 0.000 claims description 8
206010020751 Hypersensitivity Diseases 0.000 claims description 8
108010002386 Interleukin-3 Proteins 0.000 claims description 8
108010002586 Interleukin-7 Proteins 0.000 claims description 8
206010028703 Nail psoriasis Diseases 0.000 claims description 8
208000006673 asthma Diseases 0.000 claims description 8
102100036150 C-X-C motif chemokine 5 Human genes 0.000 claims description 7
206010012438 Dermatitis atopic Diseases 0.000 claims description 7
208000001640 Fibromyalgia Diseases 0.000 claims description 7
101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 claims description 7
101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 claims description 7
230000007815 allergy Effects 0.000 claims description 7
208000007502 anemia Diseases 0.000 claims description 7
201000008937 atopic dermatitis Diseases 0.000 claims description 7
208000015122 neurodegenerative disease Diseases 0.000 claims description 7
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
206010006895 Cachexia Diseases 0.000 claims description 6
208000024172 Cardiovascular disease Diseases 0.000 claims description 6
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 6
108050003558 Interleukin-17 Proteins 0.000 claims description 6
102000013691 Interleukin-17 Human genes 0.000 claims description 6
108010002335 Interleukin-9 Proteins 0.000 claims description 6
208000019693 Lung disease Diseases 0.000 claims description 6
206010037575 Pustular psoriasis Diseases 0.000 claims description 6
208000006011 Stroke Diseases 0.000 claims description 6
208000026935 allergic disease Diseases 0.000 claims description 6
201000001320 Atherosclerosis Diseases 0.000 claims description 5
206010010744 Conjunctivitis allergic Diseases 0.000 claims description 5
201000004624 Dermatitis Diseases 0.000 claims description 5
206010016654 Fibrosis Diseases 0.000 claims description 5
102000003810 Interleukin-18 Human genes 0.000 claims description 5
108090000171 Interleukin-18 Proteins 0.000 claims description 5
208000002205 allergic conjunctivitis Diseases 0.000 claims description 5
208000024998 atopic conjunctivitis Diseases 0.000 claims description 5
206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 4
206010012455 Dermatitis exfoliative Diseases 0.000 claims description 4
206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
208000018522 Gastrointestinal disease Diseases 0.000 claims description 4
206010024229 Leprosy Diseases 0.000 claims description 4
208000001647 Renal Insufficiency Diseases 0.000 claims description 4
206010046851 Uveitis Diseases 0.000 claims description 4
206010002906 aortic stenosis Diseases 0.000 claims description 4
230000004761 fibrosis Effects 0.000 claims description 4
208000017169 kidney disease Diseases 0.000 claims description 4
201000006370 kidney failure Diseases 0.000 claims description 4
208000019423 liver disease Diseases 0.000 claims description 4
208000030159 metabolic disease Diseases 0.000 claims description 4
230000001185 psoriatic effect Effects 0.000 claims description 4
230000005855 radiation Effects 0.000 claims description 4
208000020084 Bone disease Diseases 0.000 claims description 3
206010063094 Cerebral malaria Diseases 0.000 claims description 3
201000005505 Measles Diseases 0.000 claims description 3
206010033645 Pancreatitis Diseases 0.000 claims description 3
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
238000002512 chemotherapy Methods 0.000 claims description 3
208000016097 disease of metabolism Diseases 0.000 claims description 3
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
208000030533 eye disease Diseases 0.000 claims description 2
206010025135 lupus erythematosus Diseases 0.000 claims description 2
230000004968 inflammatory condition Effects 0.000 abstract 1
239000003814 drug Substances 0.000 description 78
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 77
210000004027 cell Anatomy 0.000 description 65
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 56
229940079593 drug Drugs 0.000 description 55
229910052757 nitrogen Inorganic materials 0.000 description 51
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 44
239000002904 solvent Substances 0.000 description 44
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
238000006243 chemical reaction Methods 0.000 description 41
201000010099 disease Diseases 0.000 description 41
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 40
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 38
238000011282 treatment Methods 0.000 description 38
239000000243 solution Substances 0.000 description 37
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
102000001301 EGF receptor Human genes 0.000 description 36
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 34
230000000694 effects Effects 0.000 description 33
108060006698 EGF receptor Proteins 0.000 description 31
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 31
210000003491 skin Anatomy 0.000 description 31
238000004519 manufacturing process Methods 0.000 description 30
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 29
230000001965 increasing effect Effects 0.000 description 27
230000004054 inflammatory process Effects 0.000 description 27
206010061218 Inflammation Diseases 0.000 description 26
235000019439 ethyl acetate Nutrition 0.000 description 26
230000002757 inflammatory effect Effects 0.000 description 26
239000004480 active ingredient Substances 0.000 description 25
239000002585 base Substances 0.000 description 25
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 24
239000000126 substance Substances 0.000 description 24
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 23
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 23
229940095074 cyclic amp Drugs 0.000 description 23
125000001424 substituent group Chemical group 0.000 description 23
238000012360 testing method Methods 0.000 description 23
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
210000000282 nail Anatomy 0.000 description 22
150000003254 radicals Chemical class 0.000 description 22
102000005962 receptors Human genes 0.000 description 21
108020003175 receptors Proteins 0.000 description 21
229940124597 therapeutic agent Drugs 0.000 description 21
229960001340 histamine Drugs 0.000 description 20
239000000651 prodrug Substances 0.000 description 19
229940002612 prodrug Drugs 0.000 description 19
239000013543 active substance Substances 0.000 description 18
239000002775 capsule Substances 0.000 description 18
241000282414 Homo sapiens Species 0.000 description 17
239000000872 buffer Substances 0.000 description 17
210000004209 hair Anatomy 0.000 description 17
210000000003 hoof Anatomy 0.000 description 17
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 17
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 16
210000000078 claw Anatomy 0.000 description 16
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
208000024891 symptom Diseases 0.000 description 16
239000003826 tablet Substances 0.000 description 16
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 15
125000004429 atom Chemical group 0.000 description 15
230000014509 gene expression Effects 0.000 description 15
239000012044 organic layer Substances 0.000 description 15
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 15
102000000589 Interleukin-1 Human genes 0.000 description 14
108010002352 Interleukin-1 Proteins 0.000 description 14
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 14
102000003923 Protein Kinase C Human genes 0.000 description 14
108090000315 Protein Kinase C Proteins 0.000 description 14
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 14
239000012267 brine Substances 0.000 description 14
125000005842 heteroatom Chemical group 0.000 description 14
230000005764 inhibitory process Effects 0.000 description 14
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 14
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
239000000758 substrate Substances 0.000 description 14
230000001225 therapeutic effect Effects 0.000 description 14
239000003981 vehicle Substances 0.000 description 14
229910052727 yttrium Inorganic materials 0.000 description 14
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 13
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 13
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 13
101000843809 Homo sapiens Hydroxycarboxylic acid receptor 2 Proteins 0.000 description 13
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
239000002253 acid Substances 0.000 description 13
230000004913 activation Effects 0.000 description 13
102000004190 Enzymes Human genes 0.000 description 12
108090000790 Enzymes Proteins 0.000 description 12
102100030643 Hydroxycarboxylic acid receptor 2 Human genes 0.000 description 12
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
239000003795 chemical substances by application Substances 0.000 description 12
229940088598 enzyme Drugs 0.000 description 12
239000002609 medium Substances 0.000 description 12
230000000770 proinflammatory effect Effects 0.000 description 12
210000001519 tissue Anatomy 0.000 description 12
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 11
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
208000002193 Pain Diseases 0.000 description 11
125000004432 carbon atom Chemical group C* 0.000 description 11
206010009887 colitis Diseases 0.000 description 11
238000013270 controlled release Methods 0.000 description 11
208000015181 infectious disease Diseases 0.000 description 11
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 11
238000010521 absorption reaction Methods 0.000 description 10
239000012131 assay buffer Substances 0.000 description 10
QUKGYYKBILRGFE-UHFFFAOYSA-N benzyl acetate Chemical compound CC(=O)OCC1=CC=CC=C1 QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 description 10
239000008280 blood Substances 0.000 description 10
210000004369 blood Anatomy 0.000 description 10
230000006378 damage Effects 0.000 description 10
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 10
239000006186 oral dosage form Substances 0.000 description 10
239000002953 phosphate buffered saline Substances 0.000 description 10
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 10
239000000523 sample Substances 0.000 description 10
239000000741 silica gel Substances 0.000 description 10
229910002027 silica gel Inorganic materials 0.000 description 10
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
208000024827 Alzheimer disease Diseases 0.000 description 9
206010009900 Colitis ulcerative Diseases 0.000 description 9
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
102000007399 Nuclear hormone receptor Human genes 0.000 description 9
208000018737 Parkinson disease Diseases 0.000 description 9
201000006704 Ulcerative Colitis Diseases 0.000 description 9
230000001154 acute effect Effects 0.000 description 9
230000003110 anti-inflammatory effect Effects 0.000 description 9
230000027455 binding Effects 0.000 description 9
239000000969 carrier Substances 0.000 description 9
235000019441 ethanol Nutrition 0.000 description 9
229910052760 oxygen Inorganic materials 0.000 description 9
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 9
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 9
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 9
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 8
101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 8
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
108010029485 Protein Isoforms Proteins 0.000 description 8
102000001708 Protein Isoforms Human genes 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
102100024324 Toll-like receptor 3 Human genes 0.000 description 8
NXQGGXCHGDYOHB-UHFFFAOYSA-L [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (II) Substances [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 8
230000009471 action Effects 0.000 description 8
230000000903 blocking effect Effects 0.000 description 8
208000037976 chronic inflammation Diseases 0.000 description 8
230000006020 chronic inflammation Effects 0.000 description 8
150000002148 esters Chemical class 0.000 description 8
239000001963 growth medium Substances 0.000 description 8
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 8
125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
239000003112 inhibitor Substances 0.000 description 8
230000001404 mediated effect Effects 0.000 description 8
229960003512 nicotinic acid Drugs 0.000 description 8
235000001968 nicotinic acid Nutrition 0.000 description 8
239000011664 nicotinic acid Substances 0.000 description 8
229910000027 potassium carbonate Inorganic materials 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
241000894007 species Species 0.000 description 8
229910052717 sulfur Inorganic materials 0.000 description 8
208000011231 Crohn disease Diseases 0.000 description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
201000001263 Psoriatic Arthritis Diseases 0.000 description 7
208000036824 Psoriatic arthropathy Diseases 0.000 description 7
238000003556 assay Methods 0.000 description 7
239000011575 calcium Substances 0.000 description 7
239000006071 cream Substances 0.000 description 7
125000004122 cyclic group Chemical group 0.000 description 7
239000000539 dimer Substances 0.000 description 7
239000008187 granular material Substances 0.000 description 7
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 7
239000003446 ligand Substances 0.000 description 7
231100000252 nontoxic Toxicity 0.000 description 7
230000003000 nontoxic effect Effects 0.000 description 7
230000036407 pain Effects 0.000 description 7
125000003386 piperidinyl group Chemical group 0.000 description 7
125000006239 protecting group Chemical group 0.000 description 7
229910000029 sodium carbonate Inorganic materials 0.000 description 7
239000000725 suspension Substances 0.000 description 7
230000009885 systemic effect Effects 0.000 description 7
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
239000013638 trimer Substances 0.000 description 7
OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
102000016950 Chemokine CXCL1 Human genes 0.000 description 6
108010014419 Chemokine CXCL1 Proteins 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
102000003964 Histone deacetylase Human genes 0.000 description 6
108090000353 Histone deacetylase Proteins 0.000 description 6
241000282412 Homo Species 0.000 description 6
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
125000002252 acyl group Chemical group 0.000 description 6
125000002947 alkylene group Chemical group 0.000 description 6
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
210000003169 central nervous system Anatomy 0.000 description 6
239000012043 crude product Substances 0.000 description 6
230000007423 decrease Effects 0.000 description 6
125000000524 functional group Chemical group 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
238000001990 intravenous administration Methods 0.000 description 6
239000007788 liquid Substances 0.000 description 6
210000004379 membrane Anatomy 0.000 description 6
239000012528 membrane Substances 0.000 description 6
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
125000004430 oxygen atom Chemical group O* 0.000 description 6
230000035515 penetration Effects 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
239000007787 solid Substances 0.000 description 6
239000000375 suspending agent Substances 0.000 description 6
125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 5
101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 5
241000283690 Bos taurus Species 0.000 description 5
101150039808 Egfr gene Proteins 0.000 description 5
108010008165 Etanercept Proteins 0.000 description 5
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 5
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 5
101100118549 Homo sapiens EGFR gene Proteins 0.000 description 5
102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 5
101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 5
108090000177 Interleukin-11 Proteins 0.000 description 5
102000003815 Interleukin-11 Human genes 0.000 description 5
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 5
108091000080 Phosphotransferase Proteins 0.000 description 5
102000002020 Protease-activated receptors Human genes 0.000 description 5
108050009310 Protease-activated receptors Proteins 0.000 description 5
102100037136 Proteinase-activated receptor 1 Human genes 0.000 description 5
101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 5
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 5
206010000496 acne Diseases 0.000 description 5
150000001412 amines Chemical class 0.000 description 5
239000003435 antirheumatic agent Substances 0.000 description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
239000011324 bead Substances 0.000 description 5
229940007550 benzyl acetate Drugs 0.000 description 5
108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 5
230000004071 biological effect Effects 0.000 description 5
210000000988 bone and bone Anatomy 0.000 description 5
201000011510 cancer Diseases 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
239000002988 disease modifying antirheumatic drug Substances 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
239000003937 drug carrier Substances 0.000 description 5
229940088679 drug related substance Drugs 0.000 description 5
239000003995 emulsifying agent Substances 0.000 description 5
239000003623 enhancer Substances 0.000 description 5
239000012091 fetal bovine serum Substances 0.000 description 5
230000006870 function Effects 0.000 description 5
125000004474 heteroalkylene group Chemical group 0.000 description 5
239000001257 hydrogen Substances 0.000 description 5
239000005457 ice water Substances 0.000 description 5
238000000099 in vitro assay Methods 0.000 description 5
229910052738 indium Inorganic materials 0.000 description 5
208000014674 injury Diseases 0.000 description 5
238000007918 intramuscular administration Methods 0.000 description 5
239000006210 lotion Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
239000012299 nitrogen atmosphere Substances 0.000 description 5
125000004433 nitrogen atom Chemical group N* 0.000 description 5
239000001301 oxygen Substances 0.000 description 5
238000007911 parenteral administration Methods 0.000 description 5
239000002245 particle Substances 0.000 description 5
239000008188 pellet Substances 0.000 description 5
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 5
102000020233 phosphotransferase Human genes 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
229920000642 polymer Polymers 0.000 description 5
230000002265 prevention Effects 0.000 description 5
239000000047 product Substances 0.000 description 5
238000000746 purification Methods 0.000 description 5
230000019491 signal transduction Effects 0.000 description 5
150000003431 steroids Chemical group 0.000 description 5
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 5
238000011200 topical administration Methods 0.000 description 5
RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 5
238000005406 washing Methods 0.000 description 5
SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 4
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
208000002874 Acne Vulgaris Diseases 0.000 description 4
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
241000283707 Capra Species 0.000 description 4
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 4
UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 4
101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 4
102000009024 Epidermal Growth Factor Human genes 0.000 description 4
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 4
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 4
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
239000007995 HEPES buffer Substances 0.000 description 4
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 4
108010044467 Isoenzymes Proteins 0.000 description 4
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
238000005481 NMR spectroscopy Methods 0.000 description 4
208000001132 Osteoporosis Diseases 0.000 description 4
101150098694 PDE5A gene Proteins 0.000 description 4
208000003251 Pruritus Diseases 0.000 description 4
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 4
206010039085 Rhinitis allergic Diseases 0.000 description 4
206010040070 Septic Shock Diseases 0.000 description 4
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
102100040247 Tumor necrosis factor Human genes 0.000 description 4
239000008186 active pharmaceutical agent Substances 0.000 description 4
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 4
229950006790 adenosine phosphate Drugs 0.000 description 4
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 4
201000000028 adult respiratory distress syndrome Diseases 0.000 description 4
125000003545 alkoxy group Chemical group 0.000 description 4
201000010105 allergic rhinitis Diseases 0.000 description 4
150000008064 anhydrides Chemical class 0.000 description 4
238000010171 animal model Methods 0.000 description 4
230000004888 barrier function Effects 0.000 description 4
102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 4
230000033228 biological regulation Effects 0.000 description 4
238000009835 boiling Methods 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 4
229910052799 carbon Inorganic materials 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
230000003197 catalytic effect Effects 0.000 description 4
239000000460 chlorine Substances 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
238000000576 coating method Methods 0.000 description 4
239000002537 cosmetic Substances 0.000 description 4
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
230000016396 cytokine production Effects 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
230000003111 delayed effect Effects 0.000 description 4
206010012601 diabetes mellitus Diseases 0.000 description 4
150000001982 diacylglycerols Chemical class 0.000 description 4
238000009792 diffusion process Methods 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
229940028334 follicle stimulating hormone Drugs 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
150000004677 hydrates Chemical class 0.000 description 4
229960003444 immunosuppressant agent Drugs 0.000 description 4
239000003018 immunosuppressive agent Substances 0.000 description 4
230000001976 improved effect Effects 0.000 description 4
239000000411 inducer Substances 0.000 description 4
208000027866 inflammatory disease Diseases 0.000 description 4
239000002502 liposome Substances 0.000 description 4
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
230000007774 longterm Effects 0.000 description 4
229960000485 methotrexate Drugs 0.000 description 4
125000002757 morpholinyl group Chemical group 0.000 description 4
239000002674 ointment Substances 0.000 description 4
239000003961 penetration enhancing agent Substances 0.000 description 4
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
230000026731 phosphorylation Effects 0.000 description 4
238000006366 phosphorylation reaction Methods 0.000 description 4
239000006187 pill Substances 0.000 description 4
210000002381 plasma Anatomy 0.000 description 4
239000013641 positive control Substances 0.000 description 4
235000011056 potassium acetate Nutrition 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
210000000664 rectum Anatomy 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
230000035945 sensitivity Effects 0.000 description 4
239000011734 sodium Substances 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000012312 sodium hydride Substances 0.000 description 4
229910000104 sodium hydride Inorganic materials 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
239000011593 sulfur Substances 0.000 description 4
125000004434 sulfur atom Chemical group 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
239000004094 surface-active agent Substances 0.000 description 4
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
238000004809 thin layer chromatography Methods 0.000 description 4
230000037317 transdermal delivery Effects 0.000 description 4
238000001890 transfection Methods 0.000 description 4
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
239000000080 wetting agent Substances 0.000 description 4
238000005160 1H NMR spectroscopy Methods 0.000 description 3
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
244000215068 Acacia senegal Species 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
206010003210 Arteriosclerosis Diseases 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
206010012442 Dermatitis contact Diseases 0.000 description 3
206010012735 Diarrhoea Diseases 0.000 description 3
101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 description 3
101100135859 Dictyostelium discoideum regA gene Proteins 0.000 description 3
101001117089 Drosophila melanogaster Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1 Proteins 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
102400001368 Epidermal growth factor Human genes 0.000 description 3
101800003838 Epidermal growth factor Proteins 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
108091006027 G proteins Proteins 0.000 description 3
102000030782 GTP binding Human genes 0.000 description 3
108091000058 GTP-Binding Proteins 0.000 description 3
229920000084 Gum arabic Polymers 0.000 description 3
101000988424 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4B Proteins 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
108010053914 KATP Channels Proteins 0.000 description 3
102000016924 KATP Channels Human genes 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 3
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
241001494479 Pecora Species 0.000 description 3
101100082606 Plasmodium falciparum (isolate 3D7) PDEbeta gene Proteins 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
102000001253 Protein Kinase Human genes 0.000 description 3
206010037660 Pyrexia Diseases 0.000 description 3
101100135860 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDE2 gene Proteins 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
206010047249 Venous thrombosis Diseases 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
230000005856 abnormality Effects 0.000 description 3
235000010489 acacia gum Nutrition 0.000 description 3
239000000205 acacia gum Substances 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
239000000654 additive Substances 0.000 description 3
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 3
239000000556 agonist Substances 0.000 description 3
235000010443 alginic acid Nutrition 0.000 description 3
239000000783 alginic acid Substances 0.000 description 3
229920000615 alginic acid Polymers 0.000 description 3
229960001126 alginic acid Drugs 0.000 description 3
150000004781 alginic acids Chemical class 0.000 description 3
239000003963 antioxidant agent Substances 0.000 description 3
238000013459 approach Methods 0.000 description 3
125000003710 aryl alkyl group Chemical group 0.000 description 3
208000010668 atopic eczema Diseases 0.000 description 3
230000008901 benefit Effects 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
102000011262 beta-Adrenergic Receptor Kinases Human genes 0.000 description 3
108010037997 beta-Adrenergic Receptor Kinases Proteins 0.000 description 3
IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 3
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
239000004327 boric acid Substances 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
102100029168 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Human genes 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000007894 caplet Substances 0.000 description 3
229950005499 carbon tetrachloride Drugs 0.000 description 3
239000012876 carrier material Substances 0.000 description 3
125000001309 chloro group Chemical group Cl* 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
208000010247 contact dermatitis Diseases 0.000 description 3
208000029078 coronary artery disease Diseases 0.000 description 3
239000003246 corticosteroid Substances 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
239000003596 drug target Substances 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
229940073621 enbrel Drugs 0.000 description 3
201000002491 encephalomyelitis Diseases 0.000 description 3
229940116977 epidermal growth factor Drugs 0.000 description 3
238000004299 exfoliation Methods 0.000 description 3
210000003414 extremity Anatomy 0.000 description 3
239000000945 filler Substances 0.000 description 3
238000003818 flash chromatography Methods 0.000 description 3
125000001153 fluoro group Chemical group F* 0.000 description 3
230000003325 follicular Effects 0.000 description 3
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
239000003205 fragrance Substances 0.000 description 3
235000021588 free fatty acids Nutrition 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
239000003102 growth factor Substances 0.000 description 3
229940048921 humira Drugs 0.000 description 3
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
229910000041 hydrogen chloride Inorganic materials 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000006698 induction Effects 0.000 description 3
239000003701 inert diluent Substances 0.000 description 3
230000028709 inflammatory response Effects 0.000 description 3
230000007803 itching Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
125000005647 linker group Chemical group 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
206010027175 memory impairment Diseases 0.000 description 3
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
239000013642 negative control Substances 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
150000005830 nonesterified fatty acids Chemical class 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
201000008482 osteoarthritis Diseases 0.000 description 3
230000007170 pathology Effects 0.000 description 3
230000035699 permeability Effects 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
230000004962 physiological condition Effects 0.000 description 3
229920000136 polysorbate Polymers 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
108060006633 protein kinase Proteins 0.000 description 3
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
125000004076 pyridyl group Chemical group 0.000 description 3
125000000719 pyrrolidinyl group Chemical group 0.000 description 3
238000001959 radiotherapy Methods 0.000 description 3
238000010992 reflux Methods 0.000 description 3
229940116176 remicade Drugs 0.000 description 3
208000037803 restenosis Diseases 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 3
229950005741 rolipram Drugs 0.000 description 3
229930195734 saturated hydrocarbon Natural products 0.000 description 3
238000013207 serial dilution Methods 0.000 description 3
239000012679 serum free medium Substances 0.000 description 3
210000000813 small intestine Anatomy 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
230000001629 suppression Effects 0.000 description 3
230000002459 sustained effect Effects 0.000 description 3
230000008961 swelling Effects 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
239000002562 thickening agent Substances 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000008733 trauma Effects 0.000 description 3
230000000472 traumatic effect Effects 0.000 description 3
CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Substances C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 3
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
230000024883 vasodilation Effects 0.000 description 3
239000008158 vegetable oil Substances 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
BIIVZMJDWXIXKN-UHFFFAOYSA-N 4-(4-bromo-3-methylanilino)benzonitrile Chemical compound C1=C(Br)C(C)=CC(NC=2C=CC(=CC=2)C#N)=C1 BIIVZMJDWXIXKN-UHFFFAOYSA-N 0.000 description 2
MMEGELSFOYDPQW-UHFFFAOYSA-N 4-bromo-3-methylaniline Chemical compound CC1=CC(N)=CC=C1Br MMEGELSFOYDPQW-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
208000009137 Behcet syndrome Diseases 0.000 description 2
239000005711 Benzoic acid Substances 0.000 description 2
239000004342 Benzoyl peroxide Substances 0.000 description 2
102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 2
206010006482 Bronchospasm Diseases 0.000 description 2
108091007914 CDKs Proteins 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
102000000584 Calmodulin Human genes 0.000 description 2
108010041952 Calmodulin Proteins 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
241000700199 Cavia porcellus Species 0.000 description 2
102000000844 Cell Surface Receptors Human genes 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
108091006146 Channels Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
208000000094 Chronic Pain Diseases 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
206010010904 Convulsion Diseases 0.000 description 2
102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
108010036949 Cyclosporine Proteins 0.000 description 2
201000003883 Cystic fibrosis Diseases 0.000 description 2
MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 2
229930195711 D-Serine Natural products 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
206010012289 Dementia Diseases 0.000 description 2
101100351286 Dictyostelium discoideum pdeE gene Proteins 0.000 description 2
206010059866 Drug resistance Diseases 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
206010014025 Ear swelling Diseases 0.000 description 2
208000005189 Embolism Diseases 0.000 description 2
206010014824 Endotoxic shock Diseases 0.000 description 2
241000283073 Equus caballus Species 0.000 description 2
229910052693 Europium Inorganic materials 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical group NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
QGWNDRXFNXRZMB-UUOKFMHZSA-K GDP(3-) Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-K 0.000 description 2
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
241000287828 Gallus gallus Species 0.000 description 2
241000699694 Gerbillinae Species 0.000 description 2
206010018364 Glomerulonephritis Diseases 0.000 description 2
201000005569 Gout Diseases 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
102000000543 Histamine Receptors Human genes 0.000 description 2
108010002059 Histamine Receptors Proteins 0.000 description 2
108010025076 Holoenzymes Proteins 0.000 description 2
101001098805 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4A Proteins 0.000 description 2
101000988423 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4C Proteins 0.000 description 2
101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 description 2
208000023105 Huntington disease Diseases 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
102000006386 Myelin Proteins Human genes 0.000 description 2
108010083674 Myelin Proteins Proteins 0.000 description 2
240000001307 Myosotis scorpioides Species 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical group [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
208000012902 Nervous system disease Diseases 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
239000012124 Opti-MEM Substances 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
229920002732 Polyanhydride Polymers 0.000 description 2
108010039918 Polylysine Proteins 0.000 description 2
206010036105 Polyneuropathy Diseases 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 2
208000000236 Prostatic Neoplasms Diseases 0.000 description 2
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
206010037075 Protozoal infections Diseases 0.000 description 2
208000006311 Pyoderma Diseases 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
206010037888 Rash pustular Diseases 0.000 description 2
241000700159 Rattus Species 0.000 description 2
206010063837 Reperfusion injury Diseases 0.000 description 2
206010038934 Retinopathy proliferative Diseases 0.000 description 2
241000219061 Rheum Species 0.000 description 2
206010040047 Sepsis Diseases 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
201000002661 Spondylitis Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
241000282898 Sus scrofa Species 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
102000006747 Transforming Growth Factor alpha Human genes 0.000 description 2
101800004564 Transforming growth factor alpha Proteins 0.000 description 2
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
239000013504 Triton X-100 Substances 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
208000024780 Urticaria Diseases 0.000 description 2
206010047115 Vasculitis Diseases 0.000 description 2
241000700605 Viruses Species 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
208000038016 acute inflammation Diseases 0.000 description 2
230000006022 acute inflammation Effects 0.000 description 2
208000005298 acute pain Diseases 0.000 description 2
229960002964 adalimumab Drugs 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
102000030621 adenylate cyclase Human genes 0.000 description 2
108060000200 adenylate cyclase Proteins 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
239000008272 agar Substances 0.000 description 2
150000001298 alcohols Chemical group 0.000 description 2
150000001350 alkyl halides Chemical class 0.000 description 2
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
239000002260 anti-inflammatory agent Substances 0.000 description 2
229940121363 anti-inflammatory agent Drugs 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
208000011775 arteriosclerosis disease Diseases 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
125000005002 aryl methyl group Chemical group 0.000 description 2
125000004104 aryloxy group Chemical group 0.000 description 2
230000001363 autoimmune Effects 0.000 description 2
230000035578 autophosphorylation Effects 0.000 description 2
229960002170 azathioprine Drugs 0.000 description 2
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
239000000440 bentonite Substances 0.000 description 2
229910000278 bentonite Inorganic materials 0.000 description 2
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
235000019400 benzoyl peroxide Nutrition 0.000 description 2
102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
238000002306 biochemical method Methods 0.000 description 2
229920002988 biodegradable polymer Polymers 0.000 description 2
239000004621 biodegradable polymer Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
208000034158 bleeding Diseases 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
206010006451 bronchitis Diseases 0.000 description 2
230000007885 bronchoconstriction Effects 0.000 description 2
244000309464 bull Species 0.000 description 2
102100037092 cAMP-specific 3',5'-cyclic phosphodiesterase 4A Human genes 0.000 description 2
102100029169 cAMP-specific 3',5'-cyclic phosphodiesterase 4C Human genes 0.000 description 2
102100029170 cAMP-specific 3',5'-cyclic phosphodiesterase 4D Human genes 0.000 description 2
229910002091 carbon monoxide Inorganic materials 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000005754 cellular signaling Effects 0.000 description 2
206010008118 cerebral infarction Diseases 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
230000014564 chemokine production Effects 0.000 description 2
235000013330 chicken meat Nutrition 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
229960001265 ciclosporin Drugs 0.000 description 2
230000019771 cognition Effects 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
239000003086 colorant Substances 0.000 description 2
229940125773 compound 10 Drugs 0.000 description 2
229940125898 compound 5 Drugs 0.000 description 2
239000007891 compressed tablet Substances 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
239000013078 crystal Substances 0.000 description 2
JCWIWBWXCVGEAN-UHFFFAOYSA-L cyclopentyl(diphenyl)phosphane;dichloropalladium;iron Chemical compound [Fe].Cl[Pd]Cl.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1 JCWIWBWXCVGEAN-UHFFFAOYSA-L 0.000 description 2
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
229930182912 cyclosporin Natural products 0.000 description 2
230000002354 daily effect Effects 0.000 description 2
238000001212 derivatisation Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
238000011979 disease modifying therapy Methods 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
239000008298 dragée Substances 0.000 description 2
206010013663 drug dependence Diseases 0.000 description 2
238000002651 drug therapy Methods 0.000 description 2
239000003974 emollient agent Substances 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
210000002615 epidermis Anatomy 0.000 description 2
229960000403 etanercept Drugs 0.000 description 2
OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
230000005713 exacerbation Effects 0.000 description 2
208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000284 extract Substances 0.000 description 2
206010016256 fatigue Diseases 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
239000012595 freezing medium Substances 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
239000000499 gel Substances 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
230000012010 growth Effects 0.000 description 2
QGWNDRXFNXRZMB-UHFFFAOYSA-N guanidine diphosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O QGWNDRXFNXRZMB-UHFFFAOYSA-N 0.000 description 2
125000001188 haloalkyl group Chemical group 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
125000004446 heteroarylalkyl group Chemical group 0.000 description 2
125000005553 heteroaryloxy group Chemical group 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
239000000710 homodimer Substances 0.000 description 2
150000002431 hydrogen Chemical class 0.000 description 2
230000028993 immune response Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
238000005462 in vivo assay Methods 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
239000012442 inert solvent Substances 0.000 description 2
239000012678 infectious agent Substances 0.000 description 2
229960000598 infliximab Drugs 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000003999 initiator Substances 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000007913 intrathecal administration Methods 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
210000001503 joint Anatomy 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
210000002429 large intestine Anatomy 0.000 description 2
230000013016 learning Effects 0.000 description 2
230000003902 lesion Effects 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000008297 liquid dosage form Substances 0.000 description 2
YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
229910021645 metal ion Inorganic materials 0.000 description 2
239000004530 micro-emulsion Substances 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
239000007758 minimum essential medium Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
238000000465 moulding Methods 0.000 description 2
210000000663 muscle cell Anatomy 0.000 description 2
210000005012 myelin Anatomy 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 2
208000004296 neuralgia Diseases 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
239000002858 neurotransmitter agent Substances 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
239000012457 nonaqueous media Substances 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
239000003883 ointment base Substances 0.000 description 2
239000004006 olive oil Substances 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
239000003605 opacifier Substances 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
101150037969 pde-6 gene Proteins 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
125000004193 piperazinyl group Chemical group 0.000 description 2
229920000656 polylysine Polymers 0.000 description 2
230000007824 polyneuropathy Effects 0.000 description 2
229920005862 polyol Chemical group 0.000 description 2
150000003077 polyols Chemical group 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 2
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
FCTRVTQZOUKUIV-MCDZGGTQSA-M potassium;[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound [K+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)([O-])=O)[C@@H](O)[C@H]1O FCTRVTQZOUKUIV-MCDZGGTQSA-M 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000006785 proliferative vitreoretinopathy Effects 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
208000029561 pustule Diseases 0.000 description 2
239000001397 quillaja saponaria molina bark Substances 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000004648 relaxation of smooth muscle Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
229930182490 saponin Natural products 0.000 description 2
150000007949 saponins Chemical class 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
230000037390 scarring Effects 0.000 description 2
201000000980 schizophrenia Diseases 0.000 description 2
238000000926 separation method Methods 0.000 description 2
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
208000017520 skin disease Diseases 0.000 description 2
210000002460 smooth muscle Anatomy 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
229940032147 starch Drugs 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
210000000434 stratum corneum Anatomy 0.000 description 2
TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
208000011117 substance-related disease Diseases 0.000 description 2
125000000547 substituted alkyl group Chemical group 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
210000001258 synovial membrane Anatomy 0.000 description 2
201000004595 synovitis Diseases 0.000 description 2
238000010189 synthetic method Methods 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
GIPPMBXUPCAXHC-UHFFFAOYSA-N tert-butyl n-(4-bromo-3-methylphenyl)carbamate Chemical compound CC1=CC(NC(=O)OC(C)(C)C)=CC=C1Br GIPPMBXUPCAXHC-UHFFFAOYSA-N 0.000 description 2
KRDGHEDXLQUYET-UHFFFAOYSA-N tert-butyl n-[4-bromo-3-(bromomethyl)phenyl]-n-(5-cyano-6-methoxypyridin-2-yl)carbamate Chemical compound C1=C(C#N)C(OC)=NC(N(C(=O)OC(C)(C)C)C=2C=C(CBr)C(Br)=CC=2)=C1 KRDGHEDXLQUYET-UHFFFAOYSA-N 0.000 description 2
ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
125000005309 thioalkoxy group Chemical group 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
235000010487 tragacanth Nutrition 0.000 description 2
239000000196 tragacanth Substances 0.000 description 2
229940116362 tragacanth Drugs 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
238000003146 transient transfection Methods 0.000 description 2
IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 2
239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 2
102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
230000009452 underexpressoin Effects 0.000 description 2
241000701447 unidentified baculovirus Species 0.000 description 2
125000004417 unsaturated alkyl group Chemical group 0.000 description 2
230000002792 vascular Effects 0.000 description 2
235000013311 vegetables Nutrition 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
229940058015 1,3-butylene glycol Drugs 0.000 description 1
125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
ANOOTOPTCJRUPK-UHFFFAOYSA-N 1-iodohexane Chemical compound CCCCCCI ANOOTOPTCJRUPK-UHFFFAOYSA-N 0.000 description 1
BLXSFCHWMBESKV-UHFFFAOYSA-N 1-iodopentane Chemical compound CCCCCI BLXSFCHWMBESKV-UHFFFAOYSA-N 0.000 description 1
125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
MYHNUQVKTSTVDI-UHFFFAOYSA-N 2-methyl-2-[(2-methylpropan-2-yl)oxy]propane;potassium Chemical compound [K].CC(C)(C)OC(C)(C)C MYHNUQVKTSTVDI-UHFFFAOYSA-N 0.000 description 1
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
UTUUPXBCDMQYRR-HSZRJFAPSA-N 4-[(2r)-2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine Chemical compound COC1=CC=C([C@H](CC=2C=CN=CC=2)C=2C=CC=CC=2)C=C1OC1CCCC1 UTUUPXBCDMQYRR-HSZRJFAPSA-N 0.000 description 1
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
PXACTUVBBMDKRW-UHFFFAOYSA-M 4-bromobenzenesulfonate Chemical group [O-]S(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-M 0.000 description 1
229960000549 4-dimethylaminophenol Drugs 0.000 description 1
AEKVBBNGWBBYLL-UHFFFAOYSA-N 4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1 AEKVBBNGWBBYLL-UHFFFAOYSA-N 0.000 description 1
SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
BNNMDMGPZUOOOE-UHFFFAOYSA-N 4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1 BNNMDMGPZUOOOE-UHFFFAOYSA-N 0.000 description 1
SPXOTSHWBDUUMT-UHFFFAOYSA-M 4-nitrobenzenesulfonate Chemical group [O-][N+](=O)C1=CC=C(S([O-])(=O)=O)C=C1 SPXOTSHWBDUUMT-UHFFFAOYSA-M 0.000 description 1
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
KBXROGINMXECPC-UHFFFAOYSA-N 6-[(1-hydroxy-3h-2,1-benzoxaborol-5-yl)amino]-2-methoxypyridine-3-carbonitrile Chemical compound C1=C(C#N)C(OC)=NC(NC=2C=C3COB(O)C3=CC=2)=C1 KBXROGINMXECPC-UHFFFAOYSA-N 0.000 description 1
BXDPLINBPHQTHU-UHFFFAOYSA-N 6-chloro-2-methoxypyridine-3-carbonitrile Chemical compound COC1=NC(Cl)=CC=C1C#N BXDPLINBPHQTHU-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
206010065040 AIDS dementia complex Diseases 0.000 description 1
208000007788 Acute Liver Failure Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
206010048998 Acute phase reaction Diseases 0.000 description 1
108060003345 Adrenergic Receptor Proteins 0.000 description 1
102000017910 Adrenergic receptor Human genes 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
206010001939 Aminoaciduria Diseases 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
235000011437 Amygdalus communis Nutrition 0.000 description 1
241000272525 Anas platyrhynchos Species 0.000 description 1
206010002329 Aneurysm Diseases 0.000 description 1
206010002650 Anorexia nervosa and bulimia Diseases 0.000 description 1
102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 1
101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
241000256844 Apis mellifera Species 0.000 description 1
206010051113 Arterial restenosis Diseases 0.000 description 1
206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
206010003827 Autoimmune hepatitis Diseases 0.000 description 1
206010003880 Axillary vein thrombosis Diseases 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
208000031729 Bacteremia Diseases 0.000 description 1
208000034309 Bacterial disease carrier Diseases 0.000 description 1
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
241001416153 Bos grunniens Species 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
206010006811 Bursitis Diseases 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
108010084313 CD58 Antigens Proteins 0.000 description 1
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
229940122739 Calcineurin inhibitor Drugs 0.000 description 1
101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 1
102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 1
241000282836 Camelus dromedarius Species 0.000 description 1
206010058019 Cancer Pain Diseases 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
206010007558 Cardiac failure chronic Diseases 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
208000005024 Castleman disease Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
206010008027 Cerebellar atrophy Diseases 0.000 description 1
241000282994 Cervidae Species 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical group [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
206010008531 Chills Diseases 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
206010008609 Cholangitis sclerosing Diseases 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
208000006561 Cluster Headache Diseases 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
206010009895 Colitis ischaemic Diseases 0.000 description 1
206010056979 Colitis microscopic Diseases 0.000 description 1
241000272201 Columbiformes Species 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
208000001778 Coronary Occlusion Diseases 0.000 description 1
206010011086 Coronary artery occlusion Diseases 0.000 description 1
208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
208000016192 Demyelinating disease Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
101001072031 Drosophila melanogaster Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11 Proteins 0.000 description 1
101100407340 Drosophila melanogaster Pde8 gene Proteins 0.000 description 1
101100407341 Drosophila melanogaster Pde9 gene Proteins 0.000 description 1
208000003556 Dry Eye Syndromes Diseases 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
101150029707 ERBB2 gene Proteins 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
208000032274 Encephalopathy Diseases 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
208000037487 Endotoxemia Diseases 0.000 description 1
206010058838 Enterocolitis infectious Diseases 0.000 description 1
241000283086 Equidae Species 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
108050001049 Extracellular proteins Proteins 0.000 description 1
208000020564 Eye injury Diseases 0.000 description 1
206010016717 Fistula Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
206010017076 Fracture Diseases 0.000 description 1
201000011240 Frontotemporal dementia Diseases 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
102000034354 Gi proteins Human genes 0.000 description 1
108091006101 Gi proteins Proteins 0.000 description 1
208000007465 Giant cell arteritis Diseases 0.000 description 1
201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
206010018366 Glomerulonephritis acute Diseases 0.000 description 1
206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
102100033495 Glycine dehydrogenase (decarboxylating), mitochondrial Human genes 0.000 description 1
229920002527 Glycogen Polymers 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
108010015899 Glycopeptides Proteins 0.000 description 1
102000002068 Glycopeptides Human genes 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
239000007821 HATU Substances 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
102000003834 Histamine H1 Receptors Human genes 0.000 description 1
108090000110 Histamine H1 Receptors Proteins 0.000 description 1
101000959437 Homo sapiens Beta-2 adrenergic receptor Proteins 0.000 description 1
101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
101001035752 Homo sapiens Hydroxycarboxylic acid receptor 3 Proteins 0.000 description 1
206010020365 Homocystinuria Diseases 0.000 description 1
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
102100039356 Hydroxycarboxylic acid receptor 3 Human genes 0.000 description 1
229920001612 Hydroxyethyl starch Polymers 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical group ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
206010020649 Hyperkeratosis Diseases 0.000 description 1
208000004044 Hypesthesia Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
206010021118 Hypotonia Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
208000004575 Infectious Arthritis Diseases 0.000 description 1
208000006877 Insect Bites and Stings Diseases 0.000 description 1
108010014726 Interferon Type I Proteins 0.000 description 1
102000002227 Interferon Type I Human genes 0.000 description 1
102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 description 1
101710085994 Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 description 1
102000003777 Interleukin-1 beta Human genes 0.000 description 1
108090000193 Interleukin-1 beta Proteins 0.000 description 1
208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
208000021342 Isolated sulfite oxidase deficiency Diseases 0.000 description 1
101150008942 J gene Proteins 0.000 description 1
206010023203 Joint destruction Diseases 0.000 description 1
208000001126 Keratosis Diseases 0.000 description 1
102000004016 L-Type Calcium Channels Human genes 0.000 description 1
108090000420 L-Type Calcium Channels Proteins 0.000 description 1
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 1
101710128836 Large T antigen Proteins 0.000 description 1
201000003533 Leber congenital amaurosis Diseases 0.000 description 1
208000004554 Leishmaniasis Diseases 0.000 description 1
229910010082 LiAlH Inorganic materials 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
241001233242 Lontra Species 0.000 description 1
241000406668 Loxodonta cyclotis Species 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
206010067750 Lupus pancreatitis Diseases 0.000 description 1
208000016604 Lyme disease Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
108091054455 MAP kinase family Proteins 0.000 description 1
102000043136 MAP kinase family Human genes 0.000 description 1
208000035172 MERRF Diseases 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
206010027202 Meningitis bacterial Diseases 0.000 description 1
206010027260 Meningitis viral Diseases 0.000 description 1
208000001145 Metabolic Syndrome Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
206010049567 Miller Fisher syndrome Diseases 0.000 description 1
208000034819 Mobility Limitation Diseases 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
101100407337 Mus musculus Pde8a gene Proteins 0.000 description 1
208000008238 Muscle Spasticity Diseases 0.000 description 1
206010028289 Muscle atrophy Diseases 0.000 description 1
206010028391 Musculoskeletal Pain Diseases 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
206010028570 Myelopathy Diseases 0.000 description 1
208000021908 Myocardial disease Diseases 0.000 description 1
208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
208000009525 Myocarditis Diseases 0.000 description 1
108010057466 NF-kappa B Proteins 0.000 description 1
102000003945 NF-kappa B Human genes 0.000 description 1
206010028702 Nail pitting Diseases 0.000 description 1
206010051606 Necrotising colitis Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
208000035544 Nonketotic hyperglycinaemia Diseases 0.000 description 1
241000272458 Numididae Species 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
208000022873 Ocular disease Diseases 0.000 description 1
240000007817 Olea europaea Species 0.000 description 1
208000003435 Optic Neuritis Diseases 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
206010033307 Overweight Diseases 0.000 description 1
108010070519 PAR-1 Receptor Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001111421 Pannus Species 0.000 description 1
101150003085 Pdcl gene Proteins 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
108010081690 Pertussis Toxin Proteins 0.000 description 1
208000004983 Phantom Limb Diseases 0.000 description 1
206010056238 Phantom pain Diseases 0.000 description 1
201000007100 Pharyngitis Diseases 0.000 description 1
241000286209 Phasianidae Species 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
108050008598 Phosphoesterases Proteins 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
208000000609 Pick Disease of the Brain Diseases 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
208000004550 Postoperative Pain Diseases 0.000 description 1
102000004257 Potassium Channel Human genes 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
206010036772 Proctalgia Diseases 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000010378 Pulmonary Embolism Diseases 0.000 description 1
206010037549 Purpura Diseases 0.000 description 1
241001672981 Purpura Species 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
241000283011 Rangifer Species 0.000 description 1
108091005682 Receptor kinases Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
208000033464 Reiter syndrome Diseases 0.000 description 1
241000702263 Reovirus sp. Species 0.000 description 1
208000006289 Rett Syndrome Diseases 0.000 description 1
102000014400 SH2 domains Human genes 0.000 description 1
108050003452 SH2 domains Proteins 0.000 description 1
101000935814 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) Periplasmic beta-glucosidase Proteins 0.000 description 1
208000008765 Sciatica Diseases 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
108010022999 Serine Proteases Proteins 0.000 description 1
102000012479 Serine Proteases Human genes 0.000 description 1
201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
201000010001 Silicosis Diseases 0.000 description 1
206010040893 Skin necrosis Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
206010072005 Spinal pain Diseases 0.000 description 1
241000272534 Struthio camelus Species 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
108700036932 Sulfite oxidase deficiency Proteins 0.000 description 1
206010042496 Sunburn Diseases 0.000 description 1
206010042573 Superovulation Diseases 0.000 description 1
206010042674 Swelling Diseases 0.000 description 1
229940123155 T cell inhibitor Drugs 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
108700012920 TNF Proteins 0.000 description 1
208000001106 Takayasu Arteritis Diseases 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
208000000491 Tendinopathy Diseases 0.000 description 1
206010043255 Tendonitis Diseases 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
206010043647 Thrombotic Stroke Diseases 0.000 description 1
102000002689 Toll-like receptor Human genes 0.000 description 1
108020000411 Toll-like receptor Proteins 0.000 description 1
208000000323 Tourette Syndrome Diseases 0.000 description 1
208000016620 Tourette disease Diseases 0.000 description 1
206010044248 Toxic shock syndrome Diseases 0.000 description 1
231100000650 Toxic shock syndrome Toxicity 0.000 description 1
102000009618 Transforming Growth Factors Human genes 0.000 description 1
108010009583 Transforming Growth Factors Proteins 0.000 description 1
206010048873 Traumatic arthritis Diseases 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
102000014384 Type C Phospholipases Human genes 0.000 description 1
108010079194 Type C Phospholipases Proteins 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
208000000558 Varicose Ulcer Diseases 0.000 description 1
206010047095 Vascular pain Diseases 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
208000010045 Wernicke encephalopathy Diseases 0.000 description 1
108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
UAIAYNPHPHRASK-UHFFFAOYSA-N [5-[(5-cyano-6-methoxypyridin-2-yl)-[(2-methylpropan-2-yl)oxycarbonyl]amino]-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl acetate Chemical compound C1=C(C#N)C(OC)=NC(N(C(=O)OC(C)(C)C)C=2C=C(COC(C)=O)C(B3OC(C)(C)C(C)(C)O3)=CC=2)=C1 UAIAYNPHPHRASK-UHFFFAOYSA-N 0.000 description 1
WXIONIWNXBAHRU-UHFFFAOYSA-N [dimethylamino(triazolo[4,5-b]pyridin-3-yloxy)methylidene]-dimethylazanium Chemical group C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 WXIONIWNXBAHRU-UHFFFAOYSA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000005299 abrasion Methods 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
229940124532 absorption promoter Drugs 0.000 description 1
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
208000009621 actinic keratosis Diseases 0.000 description 1
231100000851 acute glomerulonephritis Toxicity 0.000 description 1
230000004658 acute-phase response Effects 0.000 description 1
125000002015 acyclic group Chemical group 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
210000001789 adipocyte Anatomy 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000007000 age related cognitive decline Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
208000037883 airway inflammation Diseases 0.000 description 1
229960002459 alefacept Drugs 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
125000004848 alkoxyethyl group Chemical group 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
125000004414 alkyl thio group Chemical group 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
125000005237 alkyleneamino group Chemical group 0.000 description 1
125000005238 alkylenediamino group Chemical group 0.000 description 1
125000005530 alkylenedioxy group Chemical group 0.000 description 1
125000005529 alkyleneoxy group Chemical group 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
235000020224 almond Nutrition 0.000 description 1
208000004631 alopecia areata Diseases 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
229960004909 aminosalicylic acid Drugs 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
229960004238 anakinra Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000002052 anaphylactic effect Effects 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
229940127218 antiplatelet drug Drugs 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
210000001188 articular cartilage Anatomy 0.000 description 1
125000002102 aryl alkyloxo group Chemical group 0.000 description 1
125000001769 aryl amino group Chemical group 0.000 description 1
125000005101 aryl methoxy carbonyl group Chemical group 0.000 description 1
125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
125000005165 aryl thioxy group Chemical group 0.000 description 1
238000011914 asymmetric synthesis Methods 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
210000001099 axilla Anatomy 0.000 description 1
125000005604 azodicarboxylate group Chemical group 0.000 description 1
201000009904 bacterial meningitis Diseases 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000000035 biogenic effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
238000001815 biotherapy Methods 0.000 description 1
125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
238000009529 body temperature measurement Methods 0.000 description 1
230000037396 body weight Effects 0.000 description 1
208000019664 bone resorption disease Diseases 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
235000019437 butane-1,3-diol Nutrition 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
229910052792 caesium Inorganic materials 0.000 description 1
TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
230000028956 calcium-mediated signaling Effects 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000005792 cardiovascular activity Effects 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000004637 cellular stress Effects 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
210000004720 cerebrum Anatomy 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 1
201000008240 chemical colitis Diseases 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
239000012069 chiral reagent Substances 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
208000022831 chronic renal failure syndrome Diseases 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
239000004927 clay Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
208000018912 cluster headache syndrome Diseases 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
230000003930 cognitive ability Effects 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
230000000112 colonic effect Effects 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
238000003271 compound fluorescence assay Methods 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
208000026758 coronary atherosclerosis Diseases 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
238000012937 correction Methods 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
238000012136 culture method Methods 0.000 description 1
208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
108091007930 cytoplasmic receptors Proteins 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000005860 defense response to virus Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
230000008021 deposition Effects 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
238000010586 diagram Methods 0.000 description 1
239000012973 diazabicyclooctane Substances 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
150000002009 diols Chemical class 0.000 description 1
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
230000009429 distress Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
230000007783 downstream signaling Effects 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000008482 dysregulation Effects 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
229960000284 efalizumab Drugs 0.000 description 1
239000012636 effector Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
208000003401 eosinophilic granuloma Diseases 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical group C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
230000008713 feedback mechanism Effects 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
230000020764 fibrinolysis Effects 0.000 description 1
239000010408 film Substances 0.000 description 1
210000004905 finger nail Anatomy 0.000 description 1
230000003890 fistula Effects 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
201000003444 follicular lymphoma Diseases 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
238000007306 functionalization reaction Methods 0.000 description 1
230000027119 gastric acid secretion Effects 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000007897 gelcap Substances 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
229910052732 germanium Inorganic materials 0.000 description 1
GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000009229 glucose formation Effects 0.000 description 1
229940097043 glucuronic acid Drugs 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
201000011205 glycine encephalopathy Diseases 0.000 description 1
229940096919 glycogen Drugs 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
208000010758 granulomatous inflammation Diseases 0.000 description 1
210000004013 groin Anatomy 0.000 description 1
230000005283 ground state Effects 0.000 description 1
238000001631 haemodialysis Methods 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
238000011597 hartley guinea pig Methods 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000003862 health status Effects 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
230000000322 hemodialysis Effects 0.000 description 1
230000011132 hemopoiesis Effects 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
231100000234 hepatic damage Toxicity 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
208000007386 hepatic encephalopathy Diseases 0.000 description 1
125000005326 heteroaryloxy alkyl group Chemical group 0.000 description 1
125000005378 heteroarylthioxy group Chemical group 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
210000001624 hip Anatomy 0.000 description 1
239000003276 histone deacetylase inhibitor Substances 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
102000045108 human EGFR Human genes 0.000 description 1
102000053536 human HCAR2 Human genes 0.000 description 1
238000011577 humanized mouse model Methods 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
229940050526 hydroxyethylstarch Drugs 0.000 description 1
208000023399 hyperprolinemia Diseases 0.000 description 1
230000001969 hypertrophic effect Effects 0.000 description 1
208000034783 hypoesthesia Diseases 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000008076 immune mechanism Effects 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
208000027139 infectious colitis Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
210000005007 innate immune system Anatomy 0.000 description 1
230000003914 insulin secretion Effects 0.000 description 1
230000031261 interleukin-10 production Effects 0.000 description 1
230000017306 interleukin-6 production Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229940044173 iodine-125 Drugs 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
DXVOSTCYXXRQEW-UHFFFAOYSA-N iodocyclobutane Chemical compound IC1CCC1 DXVOSTCYXXRQEW-UHFFFAOYSA-N 0.000 description 1
FUCOMWZKWIEKRK-UHFFFAOYSA-N iodocyclohexane Chemical compound IC1CCCCC1 FUCOMWZKWIEKRK-UHFFFAOYSA-N 0.000 description 1
PCEBAZIVZVIQEO-UHFFFAOYSA-N iodocyclopentane Chemical compound IC1CCCC1 PCEBAZIVZVIQEO-UHFFFAOYSA-N 0.000 description 1
VLODBNNWEWTQJX-UHFFFAOYSA-N iodocyclopropane Chemical compound IC1CC1 VLODBNNWEWTQJX-UHFFFAOYSA-N 0.000 description 1
HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
239000002085 irritant Substances 0.000 description 1
230000007794 irritation Effects 0.000 description 1
208000012947 ischemia reperfusion injury Diseases 0.000 description 1
201000008222 ischemic colitis Diseases 0.000 description 1
125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
229960004184 ketamine hydrochloride Drugs 0.000 description 1
238000000021 kinase assay Methods 0.000 description 1
229940054136 kineret Drugs 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
208000037805 labour Diseases 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
230000008449 language Effects 0.000 description 1
239000010410 layer Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
210000002414 leg Anatomy 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
201000002364 leukopenia Diseases 0.000 description 1
231100001022 leukopenia Toxicity 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
230000004130 lipolysis Effects 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000008818 liver damage Effects 0.000 description 1
230000007108 local immune response Effects 0.000 description 1
238000012153 long-term therapy Methods 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
208000004341 lymphocytic colitis Diseases 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000013160 medical therapy Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
210000002418 meninge Anatomy 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
125000006682 monohaloalkyl group Chemical group 0.000 description 1
125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
201000003152 motion sickness Diseases 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
230000036640 muscle relaxation Effects 0.000 description 1
210000002464 muscle smooth vascular Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
208000025113 myeloid leukemia Diseases 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
DPHDSIQHVGSITN-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical compound C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=CC=C(F)C=C1 DPHDSIQHVGSITN-UHFFFAOYSA-N 0.000 description 1
125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
238000003333 near-infrared imaging Methods 0.000 description 1
208000004995 necrotizing enterocolitis Diseases 0.000 description 1
201000008383 nephritis Diseases 0.000 description 1
210000000885 nephron Anatomy 0.000 description 1
208000021722 neuropathic pain Diseases 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
230000003957 neurotransmitter release Effects 0.000 description 1
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
PSACHCMMPFMFAJ-UHFFFAOYSA-N nmm n-methylmorpholine Chemical compound CN1CCOCC1.CN1CCOCC1 PSACHCMMPFMFAJ-UHFFFAOYSA-N 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000010534 nucleophilic substitution reaction Methods 0.000 description 1
108010028584 nucleotidase Proteins 0.000 description 1
231100000862 numbness Toxicity 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 1
239000002997 ophthalmic solution Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000003305 oral gavage Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
208000002865 osteopetrosis Diseases 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
230000016087 ovulation Effects 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000011236 particulate material Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000035778 pathophysiological process Effects 0.000 description 1
102000007863 pattern recognition receptors Human genes 0.000 description 1
108010089193 pattern recognition receptors Proteins 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
210000004197 pelvis Anatomy 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229960002275 pentobarbital sodium Drugs 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
201000001245 periodontitis Diseases 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
238000002823 phage display Methods 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
239000002644 phorbol ester Substances 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
108091005981 phosphorylated proteins Proteins 0.000 description 1
238000001126 phototherapy Methods 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
239000000106 platelet aggregation inhibitor Substances 0.000 description 1
206010035653 pneumoconiosis Diseases 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
125000003367 polycyclic group Chemical group 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920000570 polyether Chemical group 0.000 description 1
125000006684 polyhaloalkyl group Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
230000009090 positive inotropic effect Effects 0.000 description 1
108020001213 potassium channel Proteins 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
244000144977 poultry Species 0.000 description 1
235000013594 poultry meat Nutrition 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
238000004262 preparative liquid chromatography Methods 0.000 description 1
201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
208000037821 progressive disease Diseases 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
208000002815 pulmonary hypertension Diseases 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
102000016914 ras Proteins Human genes 0.000 description 1
206010037844 rash Diseases 0.000 description 1
230000007420 reactivation Effects 0.000 description 1
208000002574 reactive arthritis Diseases 0.000 description 1
201000002793 renal fibrosis Diseases 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
208000032253 retinal ischemia Diseases 0.000 description 1
150000004492 retinoid derivatives Chemical class 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
229960002586 roflumilast Drugs 0.000 description 1
229940069575 rompun Drugs 0.000 description 1
201000005404 rubella Diseases 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
210000004761 scalp Anatomy 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
238000002821 scintillation proximity assay Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
208000010157 sclerosing cholangitis Diseases 0.000 description 1
208000008742 seborrheic dermatitis Diseases 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
201000001223 septic arthritis Diseases 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
229960001153 serine Drugs 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
210000001599 sigmoid colon Anatomy 0.000 description 1
102000034285 signal transducing proteins Human genes 0.000 description 1
108091006024 signal transducing proteins Proteins 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
230000016160 smooth muscle contraction Effects 0.000 description 1
239000003998 snake venom Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical group [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
208000018198 spasticity Diseases 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
208000020431 spinal cord injury Diseases 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
201000005671 spondyloarthropathy Diseases 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000011476 stem cell transplantation Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
210000003699 striated muscle Anatomy 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
210000003523 substantia nigra Anatomy 0.000 description 1
125000003107 substituted aryl group Chemical group 0.000 description 1
125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000007939 sustained release tablet Substances 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
230000008685 targeting Effects 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
206010043207 temporal arteritis Diseases 0.000 description 1
201000004415 tendinitis Diseases 0.000 description 1
JJXOIFHXNBFRNV-UHFFFAOYSA-N tert-butyl (2-methylpropan-2-yl)oxycarbonyl carbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C.CC(C)(C)OC(=O)OC(=O)OC(C)(C)C JJXOIFHXNBFRNV-UHFFFAOYSA-N 0.000 description 1
ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
KQABAYHHUGNEAH-UHFFFAOYSA-N tert-butyl n-(4-bromo-3-methylphenyl)-n-(4-cyanophenyl)carbamate Chemical compound C1=C(Br)C(C)=CC(N(C(=O)OC(C)(C)C)C=2C=CC(=CC=2)C#N)=C1 KQABAYHHUGNEAH-UHFFFAOYSA-N 0.000 description 1
WEHPGDDLTIPPSC-UHFFFAOYSA-N tert-butyl n-(4-bromo-3-methylphenyl)-n-(5-cyano-6-methoxypyridin-2-yl)carbamate Chemical compound C1=C(C#N)C(OC)=NC(N(C(=O)OC(C)(C)C)C=2C=C(C)C(Br)=CC=2)=C1 WEHPGDDLTIPPSC-UHFFFAOYSA-N 0.000 description 1
JLRBPHTZUSTDKS-UHFFFAOYSA-N tert-butyl n-(5-cyano-6-methoxypyridin-2-yl)-n-(1-hydroxy-3h-2,1-benzoxaborol-5-yl)carbamate Chemical compound C1=C(C#N)C(OC)=NC(N(C(=O)OC(C)(C)C)C=2C=C3COB(O)C3=CC=2)=C1 JLRBPHTZUSTDKS-UHFFFAOYSA-N 0.000 description 1
MOCRQXOJDSNSOF-UHFFFAOYSA-N tert-butyl n-[4-bromo-3-(bromomethyl)phenyl]-n-(4-cyanophenyl)carbamate Chemical compound C=1C=C(Br)C(CBr)=CC=1N(C(=O)OC(C)(C)C)C1=CC=C(C#N)C=C1 MOCRQXOJDSNSOF-UHFFFAOYSA-N 0.000 description 1
125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
150000003527 tetrahydropyrans Chemical class 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
230000008719 thickening Effects 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
210000005010 torso Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000006211 transdermal dosage form Substances 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
235000012141 vanillin Nutrition 0.000 description 1
MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
230000009723 vascular congestion Effects 0.000 description 1
230000008728 vascular permeability Effects 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
201000010044 viral meningitis Diseases 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
208000009935 visceral pain Diseases 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1
QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 1